Pharmacogenomics and Personalized Medicine
The practices of personalized medicine are to maximize the therapeutic effects of likelihood and to minimize the risk of drug toxicity for an individual patient. Pharmacogenomics is the study of the genome in drug response. The genetic disorder occurrence is quite rare in population; some might be hereditary while the others are caused by mutations. Disease-specific epigenetic signatures such as DNA methylation, hydroxymethylation, and non-coding RNAs are now being utilized clinically for prognostics and diagnostics, while an expanding collection of genetically aberrant, abnormally expressed or chromatin-interacting epigenetic enzymes are positioned as promising targets for therapeutic intervention. Scientists also recognize that even as the knowledge base continues to expand, the clinical translation of that knowledge still requires empirical evidence, generated for a particular disease and drug combination, before treatment can be customized to a patient's genotype.
- Genomic DNA and mRNA
- Serotonin transporter gene
Related Conference of Pharmacogenomics and Personalized Medicine
20th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
18th International Conference on Human Genomics and Genomic Medicine
16th International Conference on Human Genetics and Genetic Diseases
19th International Conference on Genomics & Pharmacogenomics
Pharmacogenomics and Personalized Medicine Conference Speakers
Recommended Sessions
- Animal Epigenetics
- Autoimmune Diseases
- Blood Diseases
- Cancer Epigenetics
- Cardiovascular Diseases
- Chromatin and chromosome dynamics
- Chronic Diseases
- Clinical Epigenetics
- Depression and Mental illness
- Epigenetics Biomarkers
- Epigenetics Therapy
- Gynecological and Obstetrical Diseases
- Infectious Diseases
- Kidney Diseases
- Liver Diseases
- Molecular Diagnostics of Human Diseases
- Neurodegenerative Diseases
- Pharmacogenomics and Personalized Medicine
- Plant Epigenetics
- Rare Diseases
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2025 (Italy)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (France)
- Bioinformatics - HUMAN GENOME 2025 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (France)
- Cancer and stem cells - CRISPR 2025 (Italy)
- Cancer Genomics - HUMAN GENOME 2025 (France)
- Cancer Stem Cells and Oncology - Stemgen 2026 (France)
- Cardiovascular Regeneration - Stemgen 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (France)
- Cognitive Computing - HUMAN GENOME 2025 (France)
- Computational Biology - HUMAN GENOME 2025 (France)
- CRISPR technologies and society - CRISPR 2025 (Italy)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2025 (Italy)
- Drug Detection & Development in Bioinformatics - HUMAN GENOME 2025 (France)
- Emergency Medicine - HUMAN GENOME 2025 (France)
- Epigenetics Biomarkers - HUMAN GENOME 2025 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (France)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (France)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (France)
- Genetically Modified Organisms - HUMAN GENOME 2025 (France)
- Genome editing and gene regulation in human health - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2025 (Italy)
- Genome Editing Methods and Novel Tools - CRISPR 2025 (Italy)
- Genome Mapping - HUMAN GENOME 2025 (France)
- Genomic Approach to Drug Discovery - HUMAN GENOME 2025 (France)
- Genomic Information in Medicine - HUMAN GENOME 2025 (France)
- Genomic Vaccination - HUMAN GENOME 2025 (France)
- Genomics - HUMAN GENOME 2025 (France)
- Horizons of CRISPR biology - CRISPR 2025 (Italy)
- Human Gene Therapy - HUMAN GENOME 2025 (France)
- Human Genetics - HUMAN GENOME 2025 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (France)
- Infectious Diseases - HUMAN GENOME 2025 (France)
- Medicine Genomics - HUMAN GENOME 2025 (France)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (France)
- Personalized Medicine - HUMAN GENOME 2025 (France)
- Pharma Genomics & Pharma Informatics - HUMAN GENOME 2025 (France)
- Plant and Animal Biotechnology - CRISPR 2025 (Italy)
- Preimplantation Genetic Diagnosis - HUMAN GENOME 2025 (France)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (France)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (France)
- Structural Biology and Bioinformatics - CRISPR 2025 (Italy)
- Therapeutic Genome Editing - CRISPR 2025 (Italy)